TIGIT and CD155 expression has been proposed as a marker of prognosis in several cancers [16], and in 2021, the U.S. Food and Drug Administration approved the first commercially available anti-TIGIT antibody tiragolumab. The gene discussed is PVR; the disease is cancer.